Direct interrogation of viral peptides presented by the class I HLA of HIV-infected T cells

Journal of Virology

Volumn 88, Issue 22, 2014, Pages 12992-13004

  Yaciuk, Jane C ^a   Skaley, Matthew ^a   Bardet, Wilfried ^a   Schafer, Fredda ^a   Mojsilovic, Danijela ^a   Cate, Steven ^a   Stewart, Christopher J ^a   McMurtrey, Curtis ^a   Jackson, Kenneth W ^a   Buchli, Rico ^b   Olvera, Alex ^c   Cedeño, Samandhy ^c   Plana, Montserrat ^d   Mothe, Beatriz ^c,e   Brander, Christian ^c,e,f   West, John T ^a,g   Hildebrand, William H ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b Pure Protein LLC   (United States)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

^e UNIVERSITY OF VIC CENTRAL UNIVERSITY OF CATALONIA   (Spain)

^f INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^g UNIVERSITY OF NEBRASKA LINCOLN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; HLA ANTIGEN CLASS 1; NEF PROTEIN; EPITOPE; PEPTIDE; VIRAL PROTEIN;

ANTIBODY AFFINITY; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DATA ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; INTERMETHOD COMPARISON; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; NONHUMAN; PH MEASUREMENT; PROTEIN DETERMINATION; PROTEIN FUNCTION; SEPARATION TECHNIQUE; SEQUENCE ANALYSIS; TANDEM MASS SPECTROMETRY; VIRUS IDENTIFICATION; IMMUNOLOGY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLISM; VIROLOGY;

CD4-POSITIVE T-LYMPHOCYTES; CHROMATOGRAPHY, LIQUID; EPITOPES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HIV-1; HUMANS; MASS SPECTROMETRY; PEPTIDES; VIRAL PROTEINS;

EID: 84908375017     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01914-14     Document Type: Article

References (37)

1. Cohen YZ, Dolin R. 2013. Novel HIV vaccine strategies: overview and perspective. Ther. Adv. Vaccines 1:99-112. http://dx.doi.org/10.1177/2051013613494535.
2. Fukazawa Y, Park H, Cameron MJ, Lefebvre F, Lum R, Coombes N, Mahyari E, Hagen SI, Bae JY, Reyes MD, III, Swanson T, Legasse AW, Sylwester A, Hansen SG, Smith AT, Stafova P, Shoemaker R, Li Y, Oswald K, Axthelm MK, McDermott A, Ferrari G, Montefiori DC, Edlefsen PT, Piatak M, Jr, Lifson JD, Sekaly RP, Picker LJ. 2012. Lymph node T cell responses predict the efficacy of live attenuated SIV vaccines. Nat. Med. 18:1673-1681. http://dx.doi.org/10.1038/nm.2934.
3. Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, Coyne-Johnson L, Whizin N, Oswald K, Shoemaker R, Swanson T, Legasse AW, Chiuchiolo MJ, Parks CL, Axthelm MK, Nelson JA, Jarvis MA, Piatak M, Jr, Lifson JD, Picker LJ. 2011. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473:523-527. http://dx.doi.org/10.1038/nature10003.
4. Hansen SG, Piatak M, Jr, Ventura AB, Hughes CM, Gilbride RM, Ford JC, Oswald K, Shoemaker R, Li Y, Lewis MS, Gilliam AN, Xu G, Whizin N, Burwitz BJ, Planer SL, Turner JM, Legasse AW, Axthelm MK, Nelson JA, Fruh K, Sacha JB, Estes JD, Keele BF, Edlefsen PT, Lifson JD, Picker LJ. 2013. Immune clearance of highly pathogenic SIV infection. Nature 502:100-104. http://dx.doi.org/10.1038/nature12519.
5. Okoye AA, Picker LJ. 2013. CD4(+) T-cell depletion in HIV infection: mechanisms of immunological failure. Immunol. Rev. 254:54-64. http://dx.doi.org/10.1111/imr.12066.
6. Goulder PJ, Walker BD. 2012. HIV andHLAclass I: an evolving relationship. Immunity 37:426-440. http://dx.doi.org/10.1016/j.immuni.2012.09.005.
7. Raghavan S, Selvaraj P, Swaminathan S, Narendran G. 2009. Short communication: association of HLA-A*1101 with resistance and B*4006 with susceptibility to HIV and HIV-TB: an in silico analysis of promiscuous T cell epitopes. AIDS Res. Hum. Retroviruses 25:1023-1028. http://dx.doi.org/10.1089/aid.2009.0022.
8. Llano A, Williams A, Overa A, Silva-Arrieta S, Brander C. 2013. Best-characterized HIV-1 CTL epitopes: the 2013 update, p 3-19. In Yusim K, Korber B, Brander C, Barouch D, de Boer R, Haynes BF, Koup R, Moore JP, Walker BD (ed), HIV molecular immunology 2013. Report LA-UR 13-27758. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM.
9. + T-cell responses following cytotoxic T-lymphocyte escape in chronic human immunodeficiency virus type 1 infection. J. Virol. 79:12952-12960. http://dx.doi.org/10.1128/JVI.79.20.12952-12960.2005.
10. Koizumi H, Hashimoto M, Fujiwara M, Murakoshi H, Chikata T, Borghan MA, Hachiya A, Kawashima Y, Takata H, Ueno T, Oka S, Takiguchi M. 2010. Different in vivo effects of HIV-1 immunodominant epitope-specific cytotoxic T lymphocytes on selection of escape mutant viruses. J. Virol. 84:5508-5519. http://dx.doi.org/10.1128/JVI.02483-09.
11. Ladell K, Hashimoto M, Iglesias MC, Wilmann PG, McLaren JE, Gras S, Chikata T, Kuse N, Fastenackels S, Gostick E, Bridgeman JS, Venturi V, Arkoub ZA, Agut H, van Bockel DJ, Almeida JR, Douek DC, Meyer L, Venet A, Takiguchi M, Rossjohn J, Price DA, Appay V. 2013. A molecular basis for the control of preimmune escape variants by HIVspecific CD8+T cells. Immunity 38:425-436. http://dx.doi.org/10.1016/j.immuni.2012.11.021.
12. Liu Y, Rao U, McClure J, Konopa P, Manocheewa S, Kim M, Chen L, Troyer RM, Tebit DM, Holte S, Arts EJ, Mullins JI. 2014. Impact of mutations in highly conserved amino acids of the HIV-1 Gag-p24 and Env-gp120 proteins on viral replication in different genetic backgrounds. PLoS One 9:e94240. http://dx.doi.org/10.1371/journal.pone.0094240.
13. Kawashima Y, Pfafferott K, Frater J, Matthews P, Payne R, Addo M, Gatanaga H, Fujiwara M, Hachiya A, Koizumi H, Kuse N, Oka S, Duda A, Prendergast A, Crawford H, Leslie A, Brumme Z, Brumme C, Allen T, Brander C, Kaslow R, Tang J, Hunter E, Allen S, Mulenga J, Branch S, Roach T, John M, Mallal S, Ogwu A, Shapiro R, Prado JG, Fidler S, Weber J, Pybus OG, Klenerman P, Ndung'u T, Phillips R, Heckerman D, Harrigan PR, Walker BD, Takiguchi M, Goulder P. 2009. Adaptation of HIV-1 to human leukocyte antigen class I. Nature 458:641-645. http://dx.doi.org/10.1038/nature07746.
14. Frahm N, Kiepiela P, Adams S, Linde CH, Hewitt HS, Sango K, Feeney ME, Addo MM, Lichterfeld M, Lahaie MP, Pae E, Wurcel AG, Roach T, St John MA, Altfeld M, Marincola FM, Moore C, Mallal S, Carrington M, Heckerman D, Allen TM, Mullins JI, Korber BT, Goulder PJ, Walker BD, Brander C. 2006. Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat. Immunol. 7:173-178. http://dx.doi.org/10.1038/ni1281.
15. Crowe SR, Turner SJ, Miller SC, Roberts AD, Rappolo RA, Doherty PC, Ely KH, Woodland DL. 2003. Differential antigen presentation regulates the changing patterns of CD8+ T cell immunodominance in primary and secondary influenza virus infections. J. Exp. Med. 198:399-410. http://dx.doi.org/10.1084/jem.20022151.
16. Kim S, Pinto AK, Myers NB, Hawkins O, Doll K, Kaabinejadian S, Netland J, Bevan MJ, Weidanz JA, Hildebrand WH, Diamond MS, Hansen TH. 2014. A novel T-cell receptor mimic defines dendritic cells that present an immunodominant West Nile virus epitope in mice. Eur. J. Immunol. 44:1936-1946. http://dx.doi.org/10.1002/eji.201444450.
17. Kulpa DA, Del Cid N, Peterson KA, Collins KL. 2013. Adaptor protein 1 promotes cross-presentation through the same tyrosine signal in major histocompatibility complex class I as that targeted by HIV-1. J. Virol. 87:8085-8098. http://dx.doi.org/10.1128/JVI.00701-13.
18. Kaplan C, Muller JY, Doinel C, Lefrere JJ, Paquez F, Rouger P, Salmon D, Salmon C. 1990. HLA-associated susceptibility to acquired immune deficiency syndrome in HIV-1-seropositive subjects. Hum. Hered. 40: 290-298. http://dx.doi.org/10.1159/000153947.
19. Sriwanthana B, Hodge T, Mastro TD, Dezzutti CS, Bond K, Stephens HA, Kostrikis LG, Limpakarnjanarat K, Young NL, Qari SH, Lal RB, Chandanayingyong D, McNicholl JM. 2001. HIV-specific cytotoxic T lymphocytes, HLA-A11, and chemokine-related factors may act synergistically to determine HIV resistance in CCR5 delta32-negative female sex workers in Chiang Rai, northern Thailand. AIDS Res. Hum. Retroviruses 17:719-734. http://dx.doi.org/10.1089/088922201750236997.
20. Koning FA, Jansen CA, Dekker J, Kaslow RA, Dukers N, van Baarle D, Prins M, Schuitemaker H. 2004. Correlates of resistance to HIV-1 infection in homosexual men with high-risk sexual behaviour. AIDS 18:1117-1126. http://dx.doi.org/10.1097/00002030-200405210-00005.
21. Li L, Chen W, Bouvier M. 2005. A biochemical and structural analysis of genetic diversity within the HLA-A*11 subtype. Immunogenetics 57:315-325. http://dx.doi.org/10.1007/s00251-005-0801-7.
22. Wahl A, Weidanz J, Hildebrand W. 2006. Direct class I HLA antigen discovery to distinguish virus-infected and cancerous cells. Expert Rev. Proteomics 3:641-652. http://dx.doi.org/10.1586/14789450.3.6.641.
23. Kimpton J, Emerman M. 1992. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J. Virol. 66:2232-2239.
24. Buchli R, VanGundy RS, Hickman-Miller HD, Giberson CF, Bardet W, Hildebrand WH. 2004. Real-time measurement of in vitro peptide binding to soluble HLA-A*0201 by fluorescence polarization. Biochemistry 43:14852-14863. http://dx.doi.org/10.1021/bi048580q.
25. Buchli R, VanGundy RS, Hickman-Miller HD, Giberson CF, Bardet W, Hildebrand WH. 2005. Development and validation of a fluorescence polarization-based competitive peptide-binding assay for HLAA* 0201-a new tool for epitope discovery. Biochemistry 44:12491-12507. http://dx.doi.org/10.1021/bi050255v.
26. Buchli R, Vangundy RS, Giberson CF, Hildebrand WH. 2006. Critical factors in the development of fluorescence polarization-based peptide binding assays: an equilibrium study monitoring specific peptide binding to soluble HLA-A*0201. J. Immunol. Methods 314:38-53. http://dx.doi.org/10.1016/j.jim.2006.05.010.
27. Kaufmann DE, Bailey PM, Sidney J, Wagner B, Norris PJ, Johnston MN, Cosimi LA, Addo MM, Lichterfeld M, Altfeld M, Frahm N, Brander C, Sette A, Walker BD, Rosenberg ES. 2004. Comprehensive analysis of human immunodeficiency virus type 1-specific CD4 responses reveals marked immunodominance of gag and nef and the presence of broadly recognized peptides. J. Virol. 78:4463-4477. http://dx.doi.org/10.1128/JVI.78.9.4463-4477.2004.
28. Nguyen TH, Mifsud NA, Stewart LA, Rose MJ, Etto TL, Williamson NA, Purcell AW, Kotsimbos T, Schwarer AP. 2008. Refinement in the production and purification of recombinantHCMVIE1-pp65 protein for the generation of epitope-specific T cell immunity. Protein Expr. Purif. 61:22-30. http://dx.doi.org/10.1016/j.pep.2008.05.001.
29. Schiffner T, Sattentau QJ, Dorrell L. 2013. Development of prophylactic vaccines against HIV-1. Retrovirology 10:72. http://dx.doi.org/10.1186/1742-4690-10-72.
30. Bunnik EM, Lobbrecht MS, van Nuenen AC, Schuitemaker H. 2010. Escape from autologous humoral immunity of HIV-1 is not associated with a decrease in replicative capacity. Virology 397:224-230. http://dx.doi.org/10.1016/j.virol.2009.11.009.
31. Euler Z, van Gils MJ, Bunnik EM, Phung P, Schweighardt B, Wrin T, Schuitemaker H. 2010. Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression. J. Infect. Dis. 201: 1045-1053. http://dx.doi.org/10.1086/651144.
32. van Gils MJ, Sanders RW. 2013. Broadly neutralizing antibodies against HIV-1: templates for a vaccine. Virology 435:46-56. http://dx.doi.org/10.1016/j.virol.2012.10.004.
33. Chen H, Ndhlovu ZM, Liu D, Porter LC, Fang JW, Darko S, Brockman MA, Miura T, Brumme ZL, Schneidewind A, Piechocka-Trocha A, Cesa KT, Sela J, Cung TD, Toth I, Pereyra F, Yu XG, Douek DC, Kaufmann DE, Allen TM, Walker BD. 2012. TCR clonotypes modulate the protective effect of HLA class I molecules in HIV-1 infection. Nat. Immunol. 13:691-700. http://dx.doi.org/10.1038/ni.2342.
34. Goulder PJ, Tang Y, Pelton SI, Walker BD. 2000. HLA-B57-restricted cytotoxic T-lymphocyte activity in a single infected subject toward two optimal epitopes, one of which is entirely contained within the other. J. Virol. 74:5291-5299. http://dx.doi.org/10.1128/JVI.74.11.5291-5299.2000.
35. Burrows SR, Rossjohn J, McCluskey J. 2006. Have we cut ourselves too short in mapping CTL epitopes? Trends Immunol. 27:11-16. http://dx.doi.org/10.1016/j.it.2005.11.001.
36. Mothe B, Llano A, Ibarrondo J, Daniels M, Miranda C, Zamarreno J, Bach V, Zuniga R, Perez-Alvarez S, Berger CT, Puertas MC, Martinez-Picado J, Rolland M, Farfan M, Szinger JJ, Hildebrand WH, Yang OO, Sanchez-Merino V, Brumme CJ, Brumme ZL, Heckerman D, Allen TM, Mullins JI, Gomez G, Goulder PJ, Walker BD, Gatell JM, Clotet B, Korber BT, Sanchez J, Brander C. 2011. Definition of the viral targets of protective HIV-1-specific T cell responses. J. Transl. Med. 9:208. http://dx.doi.org/10.1186/1479-5876-9-208.
37. Kloverpris HN, Payne RP, Sacha JB, Rasaiyaah JT, Chen F, Takiguchi M, Yang OO, Towers GJ, Goulder P, Prado JG. 2013. Early antigen presentation of protective HIV-1 KF11Gag and KK10Gag epitopes from incoming viral particles facilitates rapid recognition of infected cells by specific CD8+ T cells. J. Virol. 87:2628-2638. http://dx.doi.org/10.1128/JVI.02131-12.